Since we found, using cell models, that IGFBP-3 downregulation attenuated the synergism between the EGFR and SphK inhibitors, we proposed that tumor IGFBP-3 levels might act as a biomarker for the efficacy of the combination therapy (5). This evidence concerns the gene EGFR and neoplasm.